Lithium-induced nephrogenic diabetes insipidus: in vivo and in vitro studies.
The physiological basis for the polyuria and polydipsia occurring in some manic-depressive patients treated with lithium salts was studied in vivo and in vitro. Three lithium-treated polyuric patients, in whom other causes of a concentrating defect were excluded, had abnormal urinary concentrating abilities after a standard water depreviation test. Two of these patients failed to respond to exogenous vasopressin (ADH) and one had a subnormal response. The abilities of these patients to excrete solute-free water (C(H2O)) was comparable to normal subjects during steady-state water diuresis, suggesting no gross abnormalities in sodium transport. However, each of these patients demonstrated abnormally low capacities to reabsorb solute-free water (T(C) (H2O)) under hydropenic conditions after administration of hypertonic saline and vasopressin. These in vivo findings demonstrate at least a nephrogenic basis for the diabetes insipidus syndrome manifested by these three patients. The defect in water transport was further characterized in toad urinary bladders in vitro. Short-circuit current (I) and water flow (W) were studied under basal, ADH-stimulated, and cyclic adenosine 3',5'-monophosphate (c-AMP)-stimulated conditions. Increasing mucosal [Li(+)] progressively inhibited basal I, and both I and W induced by ADH. Significant inhibition of basal and ADH-induced I was observed at mucosal [Li(+)] < 1.1 mEq/liter, and of ADH-induced W at mucosal [Li(+)] = 11 mEq/liter. On the other hand, at these lithium concentrations, neither c-AMP-stimulated W nor I was inhibited. Increasing serosal [Li(+)] produced significant inhibition of basal I only at [Li(+)] at least 50-fold greater than at the mucosal (urinary) surface. These in vitro studies confirm that mucosal lithium inhibits the action of ADH, but not c-AMP. Hence, lithium appears to be a significant inhibitor of ADH-stimulated water flow, probably acts from the urinary surface, and appears to exert its effect at a site biochemically proximal to c-AMP action.
D000328:Adult; D000818:Animals; D001001:Anura; D001693:Biological Transport, Active; D001714:Bipolar Disorder / Q000188:drug therapy; D000242:Cyclic AMP; D003919:Diabetes Insipidus / Q000139:chemically induced*; D004327:Drinking Behavior / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007668:Kidney / Q000187:drug effects*; D007671:Kidney Concentrating Ability; D008094:Lithium / Q000009:adverse effects*; D008297:Male; D008564:Membrane Potentials; D008875:Middle Aged; D009994:Osmolar Concentration; D011141:Polyuria / Q000139:chemically induced; D012964:Sodium / Q000378:metabolism; D001743:Urinary Bladder / Q000187:drug effects; D014667:Vasopressins; D014882:Water-Electrolyte Balance
D014667:Vasopressins; D008094:Lithium; D012964:Sodium; D000242:Cyclic AMP